After years of Ozempic being the only registered semaglutide brand, 2026 has brought the first wave of lower-cost alternatives — plus a regulator crackdown on unsafe imitations. Here's what's real, what's coming, and what to avoid.
SAHPRA registers Rybelsus (oral semaglutide), while Ozempic continues as the only semaglutide injection sold in South Africa, used mainly for type 2 diabetes.
Novo Nordisk brings Wegovy to South Africa as the first semaglutide brand registered specifically for chronic weight management, in five dose strengths.
A joint inspection finds a Pretoria compounding pharmacy manufacturing unregistered semaglutide and tirzepatide injections with illegally imported active ingredient and no analytical testing. SAHPRA seizes stock and orders a full recall, and warns the public against unregistered "semaglutide" sellers nationwide.
South Africa's regulator confirms it is actively assessing a dozen generic semaglutide submissions from multiple manufacturers — the first real pipeline of competition to Novo Nordisk's originator products.
SAHPRA approves Sun Pharma's generic semaglutide injection — a direct generic equivalent to Ozempic — for type 2 diabetes, the first such approval in the local market.
Novo Nordisk partners with Swiss pharmaceutical company Acino to launch Extensior™, a lower-cost version of Ozempic, aimed at improving affordability and access ahead of further generic competition.
More registered manufacturers competing for the same patients typically pushes list prices down over time — that's exactly what's starting to happen with Ozempic's originator price already under pressure from Extensior, and Sun Pharma's generic still working through pharmacy rollout. We'll update our price comparison table as these products reach shelves.
These two terms get confused constantly — and the difference is a safety issue, not just a pricing one.
A generic semaglutide is manufactured to the same quality, safety and efficacy standards as the originator, tested and formally approved by SAHPRA, and sold only through licensed pharmacies against a prescription — just like Ozempic or Extensior.
A compounded "semaglutide" is mixed by a compounding pharmacy or clinic, often from imported raw active ingredient, without SAHPRA product registration or the same testing for purity, potency and sterility. SAHPRA's 2026 enforcement action found exactly these risks at one such operation.